Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival

Author:

Flouri Irini,Markatseli Theodora E.,Voulgari Paraskevi V.,Boki Kyriaki A.,Papadopoulos Ioannis,Settas Loukas,Zisopoulos Dimitrios,Skopouli Fotini N.,Iliopoulos Alexios,Bertsias George K.,Geborek Pierre,Drosos Alexandros A.,Boumpas Dimitrios T.,Sidiropoulos Prodromos

Publisher

Elsevier BV

Subject

Anesthesiology and Pain Medicine,Rheumatology

Reference45 articles.

1. Biologic therapies in rheumatology: lessons learned, future directions;Strand;Nat Rev Drug Discov,2007

2. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis;Donahue;Ann Intern Med,2008

3. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview;Singh;Can Med Assoc J,2009

4. Adverse effects of biologics: a network meta-analysis and Cochrane overview;Singh;Cochrane Database Syst Rev,2011

5. From randomized controlled trials to observational studies;Silverman;Am J Med,2009

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3